Alzamend Neuro amends warrant and preferred stock designations to ensure equity classification

Alzamend Neuro, Inc.

Entered warrant amendment with Ault Lending LLC to remove language that could prevent equity classification.
Filed Certificate of Amendment to delete liquidation preference sections from Series B Preferred designations.
Both amendments effective March 21, 2024; no other changes to terms.
Aims to align accounting treatment; does not affect holders' economic rights.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Alzamend Neuro, Inc.: Deleted sections 5(b) and 5(c) from the First Amended and Restated Certificate of Designations of Series B Convertible Preferred Stock to remove language regarding liquidation preference rights (effective 2024-03-21).

Change: charter amendment
Effective: 2024-03-21

Exact text from the filing

The COD Amendment amended the First Amended and Restated Certificate of Designations to delete sections 5(b) and 5(c) to remove certain language regarding liquidation preference rights that could have caused the Series B Convertible Preferred Stock to not be classified as equity.

View on SEC.gov

13 governance changes filed in the last 30 days. Browse all governance changes →

Alzamend Neuro, Inc. filing history →

Source: SEC EDGAR

accession 0001214659-24-005032

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.